Advertisement
Canada markets closed
  • S&P/TSX

    21,788.48
    -60.11 (-0.28%)
     
  • S&P 500

    5,469.30
    +21.43 (+0.39%)
     
  • DOW

    39,112.16
    -299.05 (-0.76%)
     
  • CAD/USD

    0.7323
    +0.0000 (+0.00%)
     
  • CRUDE OIL

    81.17
    +0.34 (+0.42%)
     
  • Bitcoin CAD

    84,566.50
    +841.36 (+1.00%)
     
  • CMC Crypto 200

    1,286.39
    +37.27 (+2.98%)
     
  • GOLD FUTURES

    2,331.20
    +0.40 (+0.02%)
     
  • RUSSELL 2000

    2,022.35
    -8.47 (-0.42%)
     
  • 10-Yr Bond

    4.2380
    -0.0100 (-0.24%)
     
  • NASDAQ futures

    19,999.00
    +26.75 (+0.13%)
     
  • VOLATILITY

    12.84
    -0.49 (-3.68%)
     
  • FTSE

    8,247.79
    -33.76 (-0.41%)
     
  • NIKKEI 225

    39,726.39
    +553.24 (+1.41%)
     
  • CAD/EUR

    0.6834
    +0.0002 (+0.03%)
     

Senseonics Holdings, Inc. to Host Business Update and Analyst Event During the American Diabetes Association’s 84th Scientific Sessions

GERMANTOWN, Md., June 13, 2024--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to host a business update and analyst event during the American Diabetes Association’s 84th Scientific Sessions in Orlando, FL.

Breakfast and refreshments will be provided beginning at 9:15 am ET on Sunday, June 23, 2024, in advance of a business update presentation from management scheduled to begin, at 10:00 am ET. Interested parties may access a live and recorded webcast of the presentation on the "Investor Relations" section of the company’s website at www.senseonics.com.

In-person attendance for the event requires advanced registration. Please email Hannah Jeffrey at hannah@gilmartinir.com by June 21, 2024, to register.

ADVERTISEMENT

About Senseonics

Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics’ CGM system Eversense® E3 includes a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240613143680/en/

Contacts

Senseonics Investor Contact
Philip Taylor
Gilmartin Group
415-937-5406
Investors@senseonics.com